Dr. D. Christopher Metzger, MD
Claim this profileWellmont Cardiology Services
Studies Peripheral Artery Disease
Studies Peripheral Arterial Disease
4 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials D. Christopher Metzger, MD is currently running
Stent Graft Systems
for Abdominal Aortic Aneurysm
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Recruiting1 award N/A5 criteria
Interventions
for Peripheral Arterial Disease
XLPAD is an observational study designed to evaluate the effectiveness and use of stent and non-stent based therapies among PAD patients. The study will create a registry that will include entry of procedural and clinical follow-up information into an online data collection software, REDCAP.Data available since Jan 1 2005 will be included in the registry, until 14,000 patients have been included. The primary objectives of this observational registry study are to: 1. Compare stent and non-stent based outcomes defined as a composite of symptom driven target vessel revascularization (TVR), unplanned surgical revascularization of the target limb and need for target limb amputation through 12 months post-index procedure (Primary efficacy endpoint) 2. Compare stent and non-stent based outcomes defined as a composite of causes such as: death, myocardial infarction (MI), stroke, peri-procedural complications, target vessel revascularization (TVR) and unplanned surgical revascularization/amputation of the target limb through 12 months (Primary safety endpoint) 3. Compare stent and non-stent based change in walking distance, Rutherford category and/or ankle- brachial index (ABI) at 12 months compared to baseline (Primary clinical improvement endpoint) Approximately 14,000patients will be enrolled at approximately 60 sites worldwide. Enrollment in the observational study will be monitored in an effort to achieve at least 20% (and no more than 80%) of the population receiving stents as the initial treatment strategy. Follow-up visits by sites will be reported at 6 and 12 months after index procedure to collect data on treatment patterns and effectiveness, and outcomes. The follow-up procedures are not mandated by the registry protocol. Each site will be encouraged to enter follow-up information derived from clinically indicated follow-up visits. All events post-index procedure till the 7th month will be reported under the 6 month follow-up form and subsequent follow-up till the 13th month post-procedure will be entered on the 12 month follow-up form. Patient management and treatment decisions are at the discretion of the care team per routine clinical practice. The procedural aspects (including selection of stent type or non-stent based treatments) and follow-up are not mandated by the registry and will be up to the discretion of the operator and/or based upon the practice dictated by the clinical care of the patient. Therefore the study poses minimal risk to the patient.
Recruiting1 award N/A2 criteria
More about D. Christopher Metzger, MD
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments D. Christopher Metzger, MD has experience with
- Non-stent Based Therapies
- Stent-based Therapies
- Alto Abdominal Stent Graft System
- FDA Approved EVAR AAA Graft Systems
- Impella®-Supported PCI
- Carotid Artery Stenting With Neuroguard IEP System
Breakdown of trials D. Christopher Metzger, MD has run
Peripheral Artery Disease
Peripheral Arterial Disease
Abdominal Aortic Aneurysm
Heart Attack
Myocardial Infarction
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does D. Christopher Metzger, MD specialize in?
D. Christopher Metzger, MD focuses on Peripheral Artery Disease and Peripheral Arterial Disease. In particular, much of their work with Peripheral Artery Disease has involved treating patients, or patients who are undergoing treatment.
Is D. Christopher Metzger, MD currently recruiting for clinical trials?
Yes, D. Christopher Metzger, MD is currently recruiting for 2 clinical trials in Kingsport Tennessee. If you're interested in participating, you should apply.
Are there any treatments that D. Christopher Metzger, MD has studied deeply?
Yes, D. Christopher Metzger, MD has studied treatments such as Non-stent based therapies, Stent-based therapies, Alto Abdominal Stent Graft System.
What is the best way to schedule an appointment with D. Christopher Metzger, MD?
Apply for one of the trials that D. Christopher Metzger, MD is conducting.
What is the office address of D. Christopher Metzger, MD?
The office of D. Christopher Metzger, MD is located at: Wellmont Cardiology Services, Kingsport, Tennessee 37660 United States. This is the address for their practice at the Wellmont Cardiology Services.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.